PHODACO 15 Drug name: PHODACO 15 Generic name: Dacomitinib Tablets/Dacmitinib

The following is the general instructions for Dacomitinib, which is for reference only. Please refer to the instructions in the drug packaging for specific use and follow the doctor's instructions.

---

Drug Name

Generic Name: Dacomitinib
Product Name: PHODACO

---

Indications

Dacomitinib is a tyrosine kinase inhibitor indicated for the following conditions:

• Non-small cell lung cancer (NSCLC) :
  First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.

---

Mechanism of action

Dacomitinib is an irreversible EGFR tyrosine kinase inhibitor that inhibits the growth and proliferation of tumor cells by blocking the signal transduction of EGFR (including mutant and wild-type), HER2 and HER4.

---

Dosage

• Recommended dose : 45 mg orally once daily.
• Dosage : Can be taken with or without food. Tablets should be swallowed whole and should not be crushed, chewed or split.

Dosage adjustments :

• If severe adverse reactions occur, the doctor may adjust the dose to 30 mg/day or 15 mg/day.

---

Precautions

1. Genetic testing :
   • Before treatment, it is necessary to confirm whether the patient carries EGFR exon 19 deletion or exon 21 L858R mutation.
2. Side Effect Monitoring :
   • Common side effects : rash, diarrhea, stomatitis, nail lesions, decreased appetite, etc.
   • Serious side effects : interstitial lung disease (ILD), dehydration or electrolyte imbalance caused by diarrhea, skin toxicity, etc.
3. Use in special populations :
   • Pregnant and lactating women : Do not use, may cause serious harm to the fetus or infant.
   • Children : Safety and effectiveness have not been established.
   • Elderly : Use with caution and monitor closely based on the patient's condition.
4. Monitoring recommendations :
   • Regularly assess lung function and skin condition.
   • Severe diarrhea or dehydration requires prompt treatment and dosage adjustment.

---

Drug interactions

• Drugs metabolized by CYP2D6 : Dacomitinib inhibits CYP2D6 activity and may increase the plasma concentrations of concomitantly used CYP2D6 substrates (such as antidepressants or cardiovascular drugs).
• Avoid concurrent use with other medications or supplements as they may increase the risk of adverse reactions.

---

Contraindications

• Patients who are allergic to dacomitinib or its excipients are contraindicated.
• It should be used with caution in patients with a history of severe lung disease (e.g., interstitial lung disease).

---

Storage conditions

• Store in a dry environment at 20°C to 25°C.
• Avoid high temperature, humidity and direct sunlight. Keep out of reach of children.

---

Important Tips

• The use of dacomitinib must be carried out under the guidance of a physician with experience in tumor treatment.
• If serious adverse reactions occur (such as lung symptoms or severe skin reactions), stop taking the drug immediately and contact your doctor.

---

Note : For more detailed information or special case medication regimens, please consult your doctor or pharmacist. If you need further explanation, please let me know!